Slides
Page 1
Investor Presentation – August 2026
Page 2
2 This presentation and the accompanying slides (the “Presentation”), which have been prepared by Concord Biotech Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness Safe Harbor
Page 3
Q1FY27 Key Financial Highlights
Page 4
Q1FY27 Key Highlights Broad based Growth • Witnessed broad based growth across All Product Categories • Growth across geographies with Exports growing by ~46% for Q1FY27 (Y-o-Y) Wallet Share Growth & Customer Acquisition • Increase in wallet share among existing customer along with Addition of New Products in existing customers • Increase in customer base with advanced discussions with large customers Robust Product Pipeline • Robust product pipeline across product categories with target to launch 2-3 products every year USFDA approval’s for ANDA’s • Approval from USFDA for its ANDA for Mycophenolate Mofetil & Tofacitinib Tablets Strengthening of Global Approvals • ANVISA inspection conducted by the Brazilian Health Regulatory Agency at manufacturing facility in Limbasi • Completed inspection by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda at Unit-II formulation facility EcoVadis Silver Medal – Sustainability Rating • Received Silver medal from EcoVadis placing Concord among the top 15% companies assessed globally Product Commercialization at Stellon Biotech • Started Commercial Operations & Sales at Stellon Biotech Injectable Ramp Up • Customer engagement at advanced levels
Page 5
5 Q1FY27 Consolidated Financial Highlights 204.0 257.5 Q1FY26 Q1FY27 +26% 61.4 82.4 Q1FY26 Q1FY27 +34% 44.1 57.7 Q1FY26 Q1FY27 +31% Q1FY26 Q1FY27 77.9% 78.9% 100 bps Q1FY26 Q1FY27 30.1% 32.0% 190 bps Q1FY26 Q1FY27 21.6% 22.4% 80 bps Gross Profit Margin (%) EBIDTA Margin (%) PAT Margin (%) Revenue (Rs. in Crs) EBITDA (Rs. in Crs) PAT (Rs. in Crs) EBIDTA margins (excluding impact of Injectable Facility & Expenses related to Stellon Biotech) stood at 37% for Q1FY27
Page 6
6 Q1FY27 Segment wise Revenue Split 153.8 218.9 Q1FY26 Q1FY27 +42% 50.2 38.6 Q1FY26 Q1FY27 -23% 204.0 257.5 Q1FY26 Q1FY27 +26% API Revenue (Rs. in Crs) Formulation Revenue (Rs. in Crs) Total Revenue (Rs. in Crs) 121.0 135.8 Q1FY26 Q1FY27 +12% 83.0 121.7 Q1FY26 Q1FY27 +46% Domestic Revenue (Rs. in Crs) Exports Revenue (Rs. in Crs) Total Revenue (Rs. in Crs) 204.0 257.5 Q1FY26 Q1FY27 +26%
Page 7
7 Management Commentary Ankur Vaid Joint Managing Director & Chief Executive Officer Commenting on the Q1 FY27 performance of the company Mr. Ankur Vaid, Joint Managing Director & Chief Executive Officer for Concord Biotech Limited said, “We are pleased to report a strong revenue growth of 26% year-on-year in Q1FY27, driven by broad-based performance across product categories and geographies. Export revenue grew by an impressive 46% year-on- year, reflecting our strong capabilities in delivering globally compliant products to regulated and semi-regulated markets. During Q1FY27, we witnessed increased business from existing customers, resulting in a higher wallet share and reinforcing our leadership in niche and complex fermentation-based molecules. We also expanded our customer base and product portfolio with the addition of new customers and products, strengthening our growth pipeline and supporting sustained revenue momentum in the coming quarters. On the regulatory front, we successfully completed inspection by ANVISA at our Limbasi facility, as well as inspections by the Pharmacy and Poisons Board (PPB) of Kenya and the National Drug Authority (NDA) of Uganda at our Unit-II formulation facility. These successful inspections further strengthen our regulatory credentials and enhance our readiness to serve global markets. Backed by the world's largest portfolio of fermentation-based products, best-in-class regulatory compliance, niche manufacturing capabilities, significant capacity, and a robust pipeline of new launches, we are confident of consistently outperforming industry growth, increasing wallet share, and strengthening our leadership position. The Company remains focused on delivering sustainable long-term growth, supported by its compliance track record, differentiated product portfolio, and expanding customer relationships. "
Page 8
8 Q1FY27 Consolidated Profit & Loss Account Profit and Loss (Rs. in Crs) Q1FY27 Q1FY26 YoY Revenue from Operations 257 204 26.2% Cost of Goods Sold 54 45 Gross Profit 203 159 27.9% Gross Profit Margin 78.9% 77.9% 100 bps Employee Cost 44 38 Other Expenses 77 60 EBITDA 82 61 34.2% EBITDA Margin 32.0% 30.1% 190 bps Depreciation 18 18 Other Income 13 14 EBIT 77 57 34.6% Finance Cost 0 0 Share in Profit/(loss) in JV and Associates 1 1 Profit before Tax 78 59 33.4% Tax 21 15 PAT 58 44 31.0% PAT Margin % 22.4% 21.6% 80 bps
Page 9
Company Overview
Page 10
10 Concord Biotech Limited is a R&D driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. Portfolio spanning 30+ Fermentation APIs 180+ Approved formulation products acrossmarkets 1 5 0 + Drug Master Files (DMFs) filed globally Fermentation capacityof 1,250m 3 Overall formulation capacityof 869Mn – OSD (incl. Softgel) 1 3 M n – Liquid Vials 1 2 M n – Dry Filling Power 2,200 kgs – Bulk Sterile Lyophilized 7 ANDAs approvedfor products from our facilities Key Highlights Expertise in Fermentation Technology ✓ Expertise in fermentation-based API manufacturing with high entry barriers ✓ One of the few global players delivering consistently in this specialized segment ✓ Built one of the largest fermentation capacities globally Continuous Investment in R&D Driven Innovation ✓ Strong focus on R&D & State-of-the-art R&D facilities. ✓ Dedicated team of scientists. ✓ Commitment to innovation enables us to stay ahead of market trends. ✓ Robust pipeline for addition of new products to meet evolving market demands Upholding the Highest Standards of Quality and Compliance ✓ World-class infrastructure adhering to global quality benchmark ✓ Facilities inspected by USFDA, EU GMP , WHO, and PMDA, Japan ✓ Presence in over 70 countries, including regulated markets Driven by Expertise and Consistent Performance ✓ Visionary leadership driving consistent growth and global expansion ✓ Evolved from single-product to multi-product company ✓ Focus on fermentation, research, manufacturing, and compliance ✓ Positioned for sustained leadership through innovation Concord Biotech at a Glance Leading & Prominent Player in Fermentation & Biotechnology World Leadership Position in Niche Fermentation based API
Page 11
11 Driving Innovation Through Our Expertise Through our strong fermentation capabilities, we produce high-quality APIs, setting us apart in biotechnology and ensuring superior efficacy in medicines Fermentation Expertise We offer full baskets of immunosuppressants in addition to our products in oncology and anti infectives making total count of 30+ fermentation-based API’s. This helps in ensuring resilience against market fluctuations and meeting diverse pharmaceutical needs effectively Diversified Portfolio Our heavy investment in R&D drives continuous process optimization, new product development, and industry leadership, fueling breakthroughs that shape the future of healthcare Commitment to Innovation Dedicated to deliver high-quality product that enhance human health, driven by innovation and customer centricity, fostering partnerships that make a meaningful impact Mission Focus Led by industry veterans. Our strategic decisions help us navigate challenges and drive sustained growth. This positions us as a trusted industry leader, committed to shaping a healthier tomorrow Visionary Leadership Rigorous adherence to regulatory standards is integral to our operations, ensuring product integrity and customer trust, bolstering our reputation as a reliable partner in healthcare Regulatory Compliance
Page 12
12 FY26 – Rs~ 829 Crores Revenue API Business Overview API Overview One of the leading global developers and manufacturers of Fermentation-based APIs Focus on Niche Fermentation API’s with backward integration to Key Starting Material Diversified Product Portfolio of API’s including Immuno-suppressant, Oncology, Anti- Infectives & Anti-Fungal Tacrolimus Mycophenolate Mofetil Mycophenolate Sodium Cyclosporine Sirolimus Pimecrolimus Everolimus Premix 2% Voclosporin Immunosuppressant Temsirolimus Everolimus Romidepsin Mitomycin Dactinomycin Staurosporin Midostaurne Everolimus Premix 9.09% Oncology Mupirocin Mupirocin Calcium Polymyxin B Sulfate Teicoplanin Vancomycin Hydrochloride Fidaxomicin Oncology Antibacterial AntibacterialAntifungal Anidulafungin CapspofunginAcetate Micafungin Sodium Amphotericin B Nystatin Antifungal`Others Lovastatin Pravastatin Sodium Enzymes Key Products FY26 – 79% Revenue Split 30+ Fermentation APIs
Page 13
13 Formulation Business Overview Formulation Overview Commercialization of Formulations business in 2016 to capitalize on the benefits of backward integration Operate through B2B model across regulated and emerging markets For India Market, operate via B2B & B2C model Oral Solid Dosages (tablets, capsules, softgel and oral suspension) Injectables (Liquid Vials, Dry Powder Filling, Bulk Sterile Lyophilized) CRITICAL CARE AmfoterolTM AnicordTM CaspoconTM MicacordTM VorixiaTM Picocord GRTM Antifungal CRITICAL CARE Dapute TM Fosutrac TM Pobix TM Teicocord TM Vanogard TM Cricolist TM Avycord TM Oncology CRITICAL CARE Gamacon TM Obulin TM RHEUMATOLOGY Conimab Gammacord Antibiotics Plasma Products Antibacterial NEPHROLOGY Tacrocord Mofecon Evercon Conimune ME Cyclograf Valocon Conimab NEPHROLOGY Darbecon Epocord Sevecord Coniron Cinacet Valolog Injecarb Key Products FY26 – Rs ~ 226 Crores Revenue FY26 – 21% Revenue Split Mepecon TM Mepecon Minocrit TM Tigicon TM Primataz TM Muprevent TM Clarinazest TM NextMatch TM Upshield Milipro Nabosis Kalcord Picatol Kanilev Lavits Antifungal AntifungalImmunology RHEUMATOLOGY Adacord Arthimide 1 Arthimide 2 Conimab 1 Conimab 2 Conimmune 25 Mabdeno Cyclograp Mofecon 250 Tacrocord 0.25 Tofajoint ER Tofajoint Unuric 40 Pricroda 180+ Approved Products Chronic Kidney DiseaseTransplant & Immuno IsacrestTM
Page 14
14 Trusted CDMO partner for Fermentation & Semi-Synthetic API’s CDMO Overview Provide contract research and manufacturing services for developing APIs and formulations. Prioritizes innovation, backed by a DSIR- certified R&D facility with a team of 180+ people Expertise in fermentation technology and strong R&D infrastructure enable us to undertake complex projects and deliver high-quality outcomes Key Strengths & Opportunities Services Include • Advanced fermentation capabilities, expertise in strain isolation and enhancement, and scalable processes • Facilitates smooth transitions from lab research to full-scale production • Specializes in Contract Research & Manufacturing, with a focus on fermentation and semi-synthesis • Ample capacities with necessary regulatory approvals to ensure smooth & consistent supply ❖ Strain Improvement ❖ Media Optimization ❖ Process Development ❖ Downstream Processing
Page 15
15 FY2000 Operations commenced 1,12,302 sq.m. Spread across 450 m3 Installed capacity Unit I (API) – Dholka, Gujarat Unit III (API) – Limbasi, Gujarat FY2021 Operations commenced 5,96,309 sq.m. Spread across 800 m3 Installed capacity Unit II (Formulations) – Valthera, Gujarat FY2016 Operations commenced 94,826 sq.m. Spread across 869Mn Units Installed capacity Pushing Boundaries through Manufacturing Capabilities Unit IV (Injectables) – Valthera, Gujarat FY2025 Operations commenced 36,441 sq.m. Spread across Installed capacity of 13Mn Liquid Vials, 12Mn Dry Power Filling & 2,200 Kgs Bulk Sterile Lyophilized
Page 16
16 Pioneering R&D Capabilities Robust pipeline of more than 10 products across different therapeutic segments of Oncology, Anti-Infectives & Anti- Fungal FormulationsR&DLab • Focus on formulation development leveraging advanced analytical capabilities. • R&D team works closely with our API experts to ensure our products meet the highest standards of quality and efficacy while providingoptimaldrugdelivery and patient convenience API R&DLab • Specialized capabilities for isolation of strains,mutation, and passive selection of microbial strains, as well as strain improvementprocesses. • Our R&D strengths enable us to drive innovation and develop new active pharmaceutical ingredients efficiently • Equippedwith fermenters and a pilot plant facility, allowingus to seamlesslyscale up fermentation processes from lab scale to commercialproduction scale. Our integrated R&D capabilities across API and formulations development allow us to bring new and innovative pharmaceutical products to the market effectively. New Product Development Cost Improvement Enhancement of Backward Integration Process Improvement Technology Transfer Scale-Up Initiatives R&D Initiatives:187 R&D Employee Strength Approved ANDA/ Finished Products API DMFs Non-Infringing Processes > 150 12/7 22+ State-of-the-Art Facilities: Where Ideas Materialise 26 30 23 27 29 2022 2023 2024 2025 2026 R&D Spends (Rs in. Crs) Spends as % of Sales 3.6% 3.5% 2.2% 2.3% 2.8%
Page 17
17 Tacrolimus ✓ ✓ ✓ ✓ ✓ Mycophenolate Mofetil ✓ ✓ ✓ ✓ ✓ Mycophenolate Sodium ✓ ✓ ✓ ✓ Cyclosporine ✓ ✓ ✓ ✓ ✓ Sirolimus ✓ ✓ ✓ ✓ Pimecrolimus ✓ Voclosporin ✓ Temsirolimus ✓ ✓ Everolimus ✓ ✓ ✓ ✓ Romidepsin ✓ ✓ Mitomycin ✓ ✓ ✓ Dactinomycin ✓ Midostaurin ✓ Mupirocin ✓ ✓ ✓ ✓ Nystatin ✓ ✓ Mupirocin Calcium ✓ ✓ ✓ Vancomycin Hydrochloride ✓ ✓ Lovastatin ✓ ✓ Pravastatin Sodium ✓ ✓ USMolecules EU Canada Japan China Immuno- SuppressantsOncologyAnti- BacterialOthers DMF Fillings Across Geographies
Page 18
18 Regulated Markets Emerging Markets Mycophenolate Mofetil Capsules Product Name ANDA Approval Mycophenolic Acid DR Tablets USP Mycophenolate Mofetil Tablets Mycophenolate Mofetil Suspension Product Name Mycophenolate Mofetil Capsules Mycophenolate Mofetil Tablets Mycophenolate Mofetil Suspension Mycophenolate Sodium 180mg Tablets Mycophenolate Sodium 360mg Tablets Tacrolimus 0.5 / 1 / 5mg Capsules Teriflunomide 7 / 14mg Tablets Tofacitinib 5 / 10mg Tablets Wide Range of Formulation Product Portfolio for Overseas Markets Tacrolimus Capsules USP Teriflunomide Tablets Tofacitinib Tablets
Page 19
19 Diversified Customer Base 70+ Countries 300+ Customers Reducing Customer Concentration % Contribution from Top 10 Customers FY24 FY23 FY22 42.0% 44.3% 47.7% Worldwide Presence Collaborative Partnerships Tailored Distribution Models FY2537.8% FY2637.6%
Page 20
20 Our Vision for Sustainability Sustainable Manufacturing Global Green Leadership Environmental Conservation The Path of Sustainability Research & Development Efficient Resource Management Constant Improvement & Adaptation Paving the Way for Sustainability Awarded Silver Medal by EcoVadis Received ISO-14001:2015 & ISO-45001:2018 Certifications Our Initiatives on Sustainability ✓ Increasing use of Renewable energy ✓ Corporate Social Responsibility ✓ Driving towards sustainable future ✓ Reduced ecological harm ✓ Improved water quality Link
Page 21
Key Business Differentiators
Page 22
22 Over 2 Decades Experience in the industry with a demonstrated track record of developing niche and complex molecules 02 1,250 M3 Fermentation Capacity across two API facilities 03 Leadership Position Leadership position for select molecules in global markets 01 30+ Fermented based API’s One of leading global developers and manufacturers of select fermentation- based APIs across immunosuppressants oncology and Anti-infectives in terms of market share 04 End-to-End Expertise in Complex Fermentation Value Chain Overview of Integrated Platform R&D Patents Key Starting Material API Manufacturing Formulations Marketing & Distribution
Page 23
23 Complex Process & Technical Expertise Significant Entry Barriers Operational Requirements (large scale fermenters) Capital Intensive Infrastructural Requirements Long gestation Period Complex technical capabilities, difficulties in scaling up operations and substantial capital investment required have resulted in significant barriers to entry in the fermentation-based API space Commercialized a wide spectrum of fermentation-based APIs Backward Integrated to KSM level Portfolio Across a Wide Range of Therapeutic Areas Scaled manufacturing facilities with a consistent regulatory compliance track record Flexible plant configuration Regulatory Approvals for global markets Concord Biotech’s Strong Capabilities 01 05040302 06 Constructing Formidable Barriers to Entry
Page 24
24 01 02 03 04 API Business CDMO Business Formulations Business Operational Efficiencies Expanding API Portfolio Marketing existing APIs to new customers Increasing wallet share with existing customers Expanding portfolio through own development & in- licensing Launching new dosage forms including injectables Expanding geographic reach in India, EMs and the US Leverage established fermentation platform, strong R&D, manufacturing and relationships with global players Trusted CDMO partner for Fermentation & Semi-Synthetic API’s Focus on process efficiency, operating leverage and product mix Key Growth Drivers Key Growth Drivers CONCORD BIOTECH Utilization & Capex to drive future growth
Page 25
For further Information, please contact Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Mr. Sagar Shroff / Mr. Vatsal Shah sagar.shroff@sgapl.net +91 98205 19303 www.sgapl.net Investor Relations Advisor: Concord Biotech Limited CIN: L24230GJ1984PLC007440 Mr. Raviraj Karia – Chief Financial Officer ravirajkaria@concordbiotech.com www.concordbiotech.com Company: